Some patients in the non-DCM group were treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blocker or angiotensin receptor-neprilysin inhibitor for secondary prevention of coronary heart disease, and some patients were treated with β-blocker as antiarrhythmic drug. This evidence concerns the gene ACE and familial dilated cardiomyopathy.